X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

UK Clinical Trials Have Plummeted In The Past Five Years

Content Team by Content Team
22nd October 2022
in Clinical Trials, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

An industry analysis on October 20th revealed that the number of clinical trials launched annually in Britain decreased by 41% between 2017 and 2021, creating a “clear and significant threat” to its reputation as a destination for clinical research.

The UK government has made a point of capitalising on clinical research carried out at the peak of the epidemic that resulted in the discovery of numerous COVID remedies, from vaccines to medications, and reaffirming its status as a worldwide science superpower. The decline in clinical trial activity, according to the Association of the British Pharmaceutical Industry (ABPI) study, painted a worrying picture.

It specifically called attention to almost half of all new late-stage trials, which are normally essential to obtaining regulatory approval for pharmaceuticals. According to the report, this moved Britain from fourth to tenth place globally for these trials. Jennifer Harris, the ABPI’s head of research policy, stated that the truth is that businesses are finding it harder to execute clinical studies in the UK and are moving rapidly elsewhere.

Like other nations, Britain’s clinical trial research ecosystem has been impacted by COVID-19’s restrictions on engagement in other disease areas, but other nations with equivalent population numbers and research ecosystems, like Spain, Germany, or France, have fared better, according to the expert.

There are differences in the pricing and licencing processes between sites, which can result in drawn-out negotiations, she added, citing the example of a corporation running global clinical research that uses trial sites throughout Britain.

Additionally, Harris said that although the UK government has implemented a national strategy, not all sites have yet embraced it. In order to ensure that there is a clear timetable within which a research is put up, she pointed out that such a standardised method exists already place in nations like Spain and France. This reduces the amount of bargaining between sites and sponsors.

The National Health System (NHS), which has long struggled with a debilitating burden on its budget, could lose out on benefits for patients and incur costs. According to the analysis, the NHS’s finances might have suffered a financial hit of up to 447 million pounds ($501 million) between 2020 and 2021 as a result of the loss of industrial research.

Previous Post

Uganda Gets Novel Antibodies, Antivirals From US For Ebola

Next Post

Rare Illness Study Will Get $38mn FDA Funding Over 4 Years

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Rare Illness Study Will Get $38mn FDA Funding Over 4 Years

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In